Many biomarkers have been identified to predict ccRCC survival and response to adjuvant systemic therapies of TKR inhibitors; however, ccRCC displays sex-bias in incidence, aggressiveness and outcomes or mortality, and it is thus important to define which of them serve as sex-specific predictors. The gene discussed is TKTL1; the disease is nonpapillary renal cell carcinoma.